Ptc Therapeutics (PTCT) Cash & Equivalents (2012 - 2026)

Ptc Therapeutics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $834.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 43.66% year-over-year to $834.0 million in Q1 2026; TTM through Mar 2026 was $834.0 million, a 43.66% decrease from a year earlier, with the FY2025 full-year figure at $984.6 million, up 26.28% from the prior year.
• Cash & Equivalents eased to $834.0 million in Q1 2026 per PTCT's latest filing, from $984.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.5 billion in Q1 2025 and bottomed at $104.4 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $548.4 million (2024), against an average of $548.2 million.
• Across the five-year window, Cash & Equivalents sank 44.99% in 2022 and soared 227.39% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $279.8 million in 2022, then soared by 112.27% to $594.0 million in 2023, then jumped by 31.26% to $779.7 million in 2024, then rose by 26.28% to $984.6 million in 2025, then declined by 15.3% to $834.0 million in 2026.
• Per Business Quant, the three latest PTCT Cash & Equivalents figures stand at $834.0 million (Q1 2026), $984.6 million (Q4 2025), and $672.6 million (Q3 2025).